Who does it compete with for the same buyer, and how do they differ?
Nexstim combines navigated presurgical mapping with TMS therapy clearances, so it competes for neurosurgical mapping buyers as well as for psychiatric therapy buyers. Its system applies nTMS mapping when a tumor is thought to be close to important motor and language areas in the patient's brain, and it holds FDA clearance for presurgical mapping of the speech and motor cortices, for major depressive disorder, and as an adjunct for OCD.
BrainsWay's 104 System pairs a stimulator with a touchscreen interface and cooling system. BrainsWay targets specific brain areas with patented H-Coils. BrainsWay's H1 coil stimulates the bilateral prefrontal cortex, favoring the left dorsolateral prefrontal cortex.
What could change its growth trajectory, and what would confirm it?
Nexstim's growth trajectory depends on converting its expanded 2026 therapy indications into system sales while research demand grows, with the June 2026 backlog as the dated indicator to watch. In 2026 it added EU certification for post-operative rehabilitation and FDA clearances for adult OCD and adolescent MDD, and additional FDA clearances expanded NBS 6 therapeutic reach beyond MDD.
TMS-EEG diagnostics and treatment development are a growing research interest, and Research and Neuroscience net sales growth came from two research systems plus a EUR 0.8 million Sinaptica license fee. Undelivered system backlog totaled seven systems at the end of June 2026.
Which risks could break the thesis, and what would warn of them?
Nexstim's disclosed risks concentrate on an unresolved royalty dispute with Magnus Medical that removes expected 2026 royalty income—the company gives no royalty-period value or financial estimate while dispute discussions continue—alongside a 14.8% year-over-year decline in therapy recurring revenue in the first half of 2026.
Customers have adopted the reusable multi-purpose head tracker of the new NBS 6 therapy system in place of disposable units. Nexstim plans for therapy recurring revenue to come increasingly from licensing agreements rather than disposable head trackers.
What does the product do for its buyer, and how is it delivered?
Nexstim sells navigated TMS systems with diagnostic, therapy, or combined functionality that customers can buy, and more than 265 diagnostic systems and more than 135 therapy-capable systems have been delivered worldwide.
The NBS 6 modular concept allows new features to be added to existing systems with ease. The brain maps aid clinicians in choosing the treatment option.

Nexstim is a medical technology company building navigated transcranial magnetic stimulation with 3D navigation targeting specific brain areas.